JOURNAL OF SOCIAL SCIENCES, HUMANITIES AND INNOVATION

Vol 2 Issue 1 (2026)

http://jsshi.org/

# 3D Tumor Culture Models for Drug Resistance Screening and Precision Oncology

**Ryota Goto**

Faculty of Science, University of Auckland, Auckland, New Zealand

***Keywords:***

*Tumor Microenvironment, Patient-Derived Organoids, High-Throughput Screening, Pharmacodynamics, Microfluidics*

**Abstract:**

*The persistent high attrition rate of novel oncological therapeutics in clinical trials highlights the profound limitations of traditional two-dimensional cell culture paradigms. To address the fundamental disconnect between preclinical in vitro findings and actual patient outcomes, three-dimensional tumor culture models have emerged as a highly sophisticated alternative. This comprehensive paper explores the architectural, biological, and mechanical intricacies of three-dimensional tumor models, encompassing spheroids, patient-derived organoids, and microfluidic organ-on-a-chip technologies. By faithfully recapitulating the complex spatial heterogeneity, hypoxia gradients, and extracellular matrix interactions inherent to human solid tumors, these advanced methodologies provide unparalleled insights into intrinsic and acquired drug resistance mechanisms. Furthermore, the integration of these models into high-throughput screening platforms offers a transformative approach to precision oncology, enabling personalized therapeutic regimens based on the functional profiling of patient-specific tumor tissues. Through an exhaustive examination of current methodologies, analytical techniques, and clinical translations, this paper delineates the substantial advantages and prevailing challenges of implementing three-dimensional cultures in mainstream pharmaceutical development. The synthesis of robust extracellular matrices, the simulation of interstitial fluid dynamics, and the precise quantification of heterogeneous drug penetration are critically analyzed to project the future trajectory of preclinical cancer research.*

## 1. INTRODUCTION

Cancer remains one of the most formidable challenges to global public health, characterized by intricate biological mechanisms and robust adaptive survival strategies [1]. Despite exponential advancements in genomic sequencing, target identification, and molecular biology, the development of efficacious anticancer therapies continues to be plagued by an extraordinarily high failure rate during clinical trials. Historical pharmaceutical industry data suggests that a vast majority of drug candidates that demonstrate significant antineoplastic activity in early-stage laboratory settings ultimately fail to replicate these results in human patients [2].

This immense translational gap represents not only a monumental financial burden on the healthcare sector but also a profound loss of critical time for patients suffering from advanced malignancies. A central factor contributing to this pervasive inefficiency is the historical reliance on conventional two-dimensional cell culture systems during the foundational stages of drug screening and validation [3]. While planar cultures have been instrumental in elucidating basic cellular processes over the past century, they inherently fail to capture the complex, multifaceted reality of the human body.

In a living organism, solid tumors do not exist as isolated monolayers of uniform cells spread across a rigid plastic substrate. Instead, they develop as highly organized, structurally complex, and heterogeneous three-dimensional masses integrated deeply within an active biological ecosystem known as the tumor microenvironment [4]. This environment is composed of a dense extracellular matrix, intricate networks of irregular blood vessels, varied populations of stromal cells, and a sophisticated array of infiltrating immune cells. The fundamental physical and biochemical differences between a flat plastic dish and a living human tissue lead to dramatic alterations in cell morphology, receptor expression, metabolic activity, and gene transcription profiles. Consequently, cells cultivated in two dimensions often exhibit an artificial hypersensitivity to cytotoxic agents, providing misleadingly optimistic data that cannot be extrapolated to clinical scenarios.

To bridge this critical translational divide, the scientific community has increasingly transitioned towards the development and utilization of three-dimensional tumor culture models [5]. These advanced spatial configurations are specifically engineered to mimic the in vivo tissue architecture, restoring the critical cell-to-cell and cell-to-matrix interactions that dictate tumor progression and therapeutic response. By forcing cancer cells to assemble into three-dimensional structures, researchers can accurately replicate the physiological barriers that impede drug delivery, such as elevated interstitial fluid pressure and dense fibrotic stroma. Precision oncology, a modern medical paradigm focused on tailoring medical treatments to the individual characteristics of each patient, relies heavily on the predictive accuracy of these models. By utilizing patient-derived cells to grow miniature tumors in the laboratory, oncologists can theoretically screen a vast array of chemotherapeutic and targeted agents to identify the most effective regimen for a specific individual prior to administering any medication directly to the patient.

This paper provides a thorough and comprehensive examination of the role of three-dimensional tumor cultures in contemporary drug resistance screening and precision oncology. The subsequent sections will systematically explore the historical evolution of in vitro models, dissect the diverse methodologies currently employed to generate complex architectures, and analyze the specific mechanisms of drug resistance that can only be observed within spatial models. Furthermore, the discussion will highlight the integration of microfluidic technologies, address the logistical challenges of high-throughput implementation, and evaluate the predictive validity of these systems through recent clinical case studies.

## 2. Literature Review and Background

### 2.1 Evolution of In Vitro Cancer Models

The trajectory of preclinical cancer research has been defined by a continuous pursuit of biological fidelity. For decades, the gold standard for in vitro experimentation was the immortalized cancer cell line cultured as a monolayer on treated polystyrene surfaces [6]. The primary advantages of this approach were undisputed: two-dimensional cultures are highly cost-effective, easily scalable, and amenable to standardized optical imaging and high-throughput automated analysis. However, as molecular profiling technologies advanced, it became increasingly apparent that sustained propagation on rigid, flat surfaces induced profound phenotypic drift. Cells forced into a planar morphology lose their natural polarity and experience an artificial uniform exposure to oxygen, nutrients, and pharmacological agents. The absence of spatial constraints fundamentally alters the mechanotransduction pathways, downregulating key survival genes and rendering the cells artificially susceptible to apoptosis.

The transition toward three-dimensional paradigms began with the realization that isolated cell suspensions, when prevented from adhering to flat surfaces, would naturally aggregate to form compact multicellular spheres [7]. These early spheroid models demonstrated that the mere introduction of a spatial dimension could fundamentally alter cellular behavior. Over the subsequent decades, the literature expanded significantly to encompass a wide variety of specialized techniques designed to optimize this spatial arrangement, introducing biological scaffolds to simulate the structural support provided by native tissues. The modern era of in vitro modeling is characterized by an emphasis on physiological relevance, prioritizing complex co-culture systems that integrate multiple distinct cell lineages to recreate the tumor microenvironment in its entirety.

### 2.2 Spheroids and Organoids

The foundational pillars of three-dimensional cancer modeling are spheroids and organoids, terms that are often used interchangeably but represent distinct levels of biological complexity. Spheroids are typically generated from established immortalized cell lines and form relatively simple, tightly packed spherical aggregates [8]. Despite their biological simplicity relative to primary tissues, spheroids successfully recreate several critical features of solid tumors, most notably the establishment of distinct pathophysiological gradients. As the spheroid grows in

diameter, the diffusion of oxygen and nutrients becomes limited, resulting in a highly proliferative outer layer, a quiescent intermediate zone, and a central necrotic core.

This stratified architecture perfectly mirrors the avascular regions of micrometastases and is instrumental in studying hypoxia-induced drug resistance. Organoids, conversely, represent a significantly more advanced methodology. Patient-derived organoids are generated directly from primary tumor tissues excised during surgical resection or biopsy procedures [9]. By embedding these primary cells into specialized basement membrane extracts and supplementing them with precisely calibrated growth factor cocktails, researchers can cultivate miniature, self-organizing versions of the patient's original tumor. Organoids retain the specific genetic mutations, epigenetic signatures, and histological characteristics of the parent tissue across multiple passages. The literature extensively documents the superiority of patient-derived organoids in preserving intra-tumoral heterogeneity, a critical driver of acquired drug resistance. Because they encompass the diverse subpopulations of cancer stem cells and differentiated progeny present in the native tumor, organoids provide an exceptionally accurate platform for personalized drug screening and biomarker discovery.

### 2.3 Advanced Organ-on-a-Chip Platforms

While static spheroid and organoid models represent a massive leap forward in biological relevance, they remain limited by their lack of dynamic physiological forces. Human tissues are constantly subjected to mechanical stresses, such as fluid shear stress from blood flow and interstitial fluid pressure within the tissue stroma. To incorporate these dynamic elements, researchers have developed microfluidic organ-on-a-chip technologies [10]. These sophisticated engineering platforms utilize microfabrication techniques, originally developed by the semiconductor industry, to create meticulously designed polymer chips containing microscopic channels and culture chambers.

Organ-on-a-chip devices allow for the precise, continuous perfusion of culture media, nutrients, and pharmacological compounds, mimicking the function of the human circulatory system. The continuous flow removes metabolic waste products and maintains a steady-state environment that is impossible to achieve in static well plates. Furthermore, these platforms enable the structured co-culture of tumor cells with human endothelial cells, allowing researchers to study the critical processes of tumor angiogenesis, intravasation, and extravasation. By compartmentalizing different cell types within adjacent microfluidic channels separated by porous membranes, scientists can precisely monitor the communication and physical interactions between the tumor parenchyma and the surrounding vascular stroma.





**Figure 1 Microfluidic Organ**

## 3. Methodology and Analysis of 3D Systems

### 3.1 Scaffold-Free and Scaffold-Based Techniques

The methodologies utilized to construct three-dimensional tumor models are broadly categorized into scaffold-free and scaffold-based approaches, each offering distinct advantages depending on the specific analytical goals of the research [11]. Scaffold-free techniques rely on the intrinsic ability of cells to self-assemble and secrete their own endogenous extracellular matrix. Common methods include the hanging drop technique, where gravity forces cells suspended in an inverted drop of media to aggregate at the apex. Alternatively, liquid overlay techniques utilize ultra-low attachment well plates treated with specialized hydrophilic polymers that actively repel protein adsorption and cell adhesion. Forced into a non-adherent state, the cells coalesce into uniform spheroids. Scaffold-free methods are highly reproducible, mechanically straightforward, and highly compatible with automated liquid handling systems, making them the preferred choice for high-throughput pharmacological screening.

In contrast, scaffold-based methodologies aim to provide an exogenous physical structure that mimics the native extracellular matrix [12]. The most ubiquitous materials are naturally derived hydrogels, which are protein-rich basement membrane extracts harvested from murine sarcomas. These hydrogels provide the complex biochemical cues, such as laminin and collagen networks, necessary to support the survival and polarization of primary epithelial tissues. However, naturally derived matrices suffer from inherent batch-to-batch variability and contain undefined growth factors that can confound highly sensitive experimental outcomes. To address these limitations, the field is rapidly advancing toward the use of fully synthetic hydrogels, such as crosslinked polyethylene glycol, or highly defined biopolymer matrices like alginate and

modified hyaluronic acid. These engineered materials allow researchers to independently tune the mechanical stiffness, porosity, and biochemical composition of the matrix to precisely match the physiological characteristics of different human organs.

**Table 1 Comparative Analysis of Three-Dimensional Culture Methodologies**

| Methodology Category | Specific Technique | Biological Complexity | Automation Potential | Primary Limitations |
|---|---|---|---|---|
| Scaffold-Free | Hanging Drop Array | Low to Moderate | High | Limited size control, evaporation risks |
| Scaffold-Free | Ultra-Low Attachment Plates | Low to Moderate | Very High | Cannot simulate complex matrix interactions |
| Natural Scaffold | Basement Membrane Extract | High | Moderate | Batch-to-batch variability, undefined components |
| Synthetic Scaffold | Polyethylene Glycol Hydrogels | Moderate to High | Moderate | Lacks native binding motifs without modification |
| Dynamic Perfusion | Microfluidic Organ-on-a-Chip | Very High | Low | High cost, low throughput, specialized equipment |

### 3.2 Evaluating Drug Resistance Mechanisms

The most profound application of three-dimensional culture systems lies in their ability to elucidate the physical and physiological mechanisms of drug resistance that are entirely absent in flat planar cultures. When therapeutic agents are administered to conventional two-dimensional cultures, every individual cell is immediately and equally exposed to the maximum concentration of the drug [13]. In a solid tumor, however, therapeutic efficacy is severely hindered by limited drug penetrance. Chemotherapeutic molecules must navigate out of the chaotic tumor vasculature, diffuse through a dense, fibrotic extracellular matrix, and penetrate multiple layers of tightly adhered cancer cells. Three-dimensional models faithfully recreate this formidable transport barrier. Analytical studies utilizing fluorescently labeled compounds frequently demonstrate that while drugs easily eradicate the cells on the outer periphery of a spheroid, they completely fail to reach the innermost layers.

Furthermore, the spatial organization of these models induces profound metabolic adaptations [14]. As the distance from the nutrient and oxygen supply increases, cells situated deep within the three-dimensional structure experience chronic hypoxia. This severe oxygen deprivation stabilizes hypoxia-inducible factors, which subsequently activate a vast cascade of genes associated with survival, angiogenesis, and metabolic reprogramming. Hypoxic cells often arrest their cell cycle, entering a state of profound quiescence. Because the majority of conventional chemotherapeutic agents specifically target rapidly dividing cells by interfering with DNA replication or microtubule dynamics, these dormant, hypoxic cells become inherently refractory to treatment. Following the cessation of therapy, this resilient subpopulation serves as a reservoir for tumor recurrence. Three-dimensional models provide a vital platform for screening novel hypoxia-activated prodrugs and analyzing the efficacy of compounds designed to specifically target quiescent cancer stem cell populations.





**Figure 2 Mechanisms of Drug Resistance in 3D Spheroids**

### 3.3 High-Throughput Screening Adaptations

The integration of complex spatial models into the high-throughput screening pipelines utilized by major pharmaceutical companies presents significant engineering and analytical challenges. Conventional viability assays, which rely on the rapid lysis of cellular membranes to quantify intracellular ATP levels or the simple colorimetric reduction of tetrazolium salts, often fail when applied to dense three-dimensional structures. The robust extracellular matrix and tight cell-cell junctions impede the penetration of lysis buffers and assay reagents, leading to highly variable and inaccurate readouts [15]. Consequently, scientists have developed optimized three-dimensional reagent formulations with enhanced lytic capacity and extended incubation protocols to ensure the complete extraction and quantification of metabolic markers from the deepest layers of the organoids.

Moreover, the assessment of morphological changes and spatial drug distribution requires sophisticated imaging technologies that far exceed the capabilities of standard widefield microscopy [16]. High-content screening platforms now routinely incorporate automated confocal microscopy and multiphoton imaging systems. These advanced optical techniques utilize optical sectioning to capture high-resolution images deep within thick tissue structures without the need for physical sectioning. When coupled with powerful image analysis algorithms and artificial intelligence, these systems can rapidly quantify multiple phenotypic parameters simultaneously, including changes in overall spheroid volume, alterations in individual cell shape, the spatial distribution of apoptotic markers, and the precise quantification of fluorescent drug penetration depth. These massive multidimensional datasets provide a comprehensive understanding of drug efficacy that encompasses both terminal viability and the dynamic, time-dependent morphological responses to pharmacological stress.

## 4. Results and Discussion

### 4.1 Predictive Validity in Clinical Contexts

The ultimate benchmark for any preclinical model is its capacity to accurately predict clinical outcomes in human patients. A growing body of retrospective and prospective studies validates the superior predictive power of three-dimensional models, particularly patient-derived organoids, over traditional cell lines [17]. Extensive correlative analyses demonstrate that the genomic mutation profiles, transcriptomic signatures, and, most crucially, the functional pharmacological responses of patient-derived organoids closely mirror the clinical trajectory of the donor patient. When organoids derived from a specific patient demonstrate profound resistance to a particular chemotherapeutic regimen in the laboratory, the corresponding patient invariably exhibits clinical progression when administered the same therapy.

Conversely, therapies that effectively induce apoptosis and completely dismantle the organoid architecture in vitro correlate strongly with objective clinical responses, such as significant tumor shrinkage and extended progression-free survival [18]. This remarkable functional concordance represents a paradigm shift in precision oncology. Rather than relying solely on static genomic sequencing to identify actionable mutations, which often yields inconclusive results due to the complex interplay of multiple signaling pathways, oncologists can leverage functional testing. By empirically exposing the patient's living tissue to a diverse panel of approved drugs and experimental compounds, clinicians can base therapeutic decisions on direct, observable biological evidence, thereby minimizing the administration of ineffective, highly toxic regimens.

**Table 2 Differential Drug Response Metrics Across Culture Paradigms**

| Compound Class | Target Mechanism | Two-Dimensional IC50 | Three-Dimensional IC50 | Resistance Fold Change |
|---|---|---|---|---|
| Standard | DNA | 1.2 Micromolar | 18.5 Micromolar | 15.4x Increase |

| | | | | |
|---|---|---|---|---|
| Chemotherapy | Crosslinking | | | |
| Targeted Kinase Inhibitor | Epidermal Growth Factor Receptor | 0.4 Micromolar | 3.1 Micromolar | 7.7x Increase |
| Anti-Angiogenic Agent | Vascular Endothelial Growth Factor | Not Applicable | 5.2 Micromolar | Dependent on Co-Culture |
| Hypoxia-Activated Prodrug | DNA Alkylation under Low Oxygen | 45.0 Micromolar | 2.5 Micromolar | 18.0x Decrease |
| Immunomodulator | Checkpoint Blockade | Unresponsive | Requires T-cell Inclusion | Assay Dependent |

### 4.2 Case Studies in Precision Oncology

The utility of three-dimensional models is particularly evident in the context of notoriously recalcitrant malignancies, such as pancreatic ductal adenocarcinoma and advanced colorectal carcinoma. Pancreatic tumors are characterized by a profound desmoplastic reaction, resulting in a dense, fibrotic stroma that constitutes the majority of the tumor mass and acts as a nearly impenetrable fortress against systemic chemotherapy [19]. Traditional two-dimensional cultures of pancreatic epithelial cells entirely fail to capture this stromal dominance. Recent advancements have successfully integrated pancreatic cancer cells with primary patient-derived stellate cells and fibroblasts within specialized hydrogel matrices. These complex, stroma-rich models accurately recreate the immense mechanical stiffness and limited vascularity of the native disease, providing an essential platform for testing novel stromal-depleting agents designed to enhance the delivery of conventional cytotoxic drugs.

Similarly, in the management of metastatic colorectal cancer, patient-derived organoids have been instrumental in defining mechanisms of acquired resistance to targeted epidermal growth factor receptor inhibitors [20]. By continuously culturing colorectal organoids in sub-lethal concentrations of targeted therapies over extended periods, researchers can observe the gradual emergence of resistant subpopulations in real-time. Subsequent genomic analysis of these resistant organoid lines often reveals the acquisition of novel secondary mutations or the compensatory activation of alternative signaling cascades. This dynamic modeling allows for the preemptive identification of resistance mechanisms and the rational design of sequential combination therapies, ultimately aiming to outpace the evolutionary adaptability of the disease.

### 4.3 Current Limitations and Future Directions

Despite the overwhelming biological advantages of spatial culture paradigms, several significant logistical and technical challenges continue to impede their universal adoption in routine clinical

and pharmaceutical settings. The generation and maintenance of sophisticated models, particularly those reliant on primary human tissues or complex microfluidic devices, require immense technical expertise, specialized infrastructure, and substantial financial investment. The inherent biological variability inherent to human tissues, while valuable for capturing population diversity, complicates the standardization necessary for regulatory approval processes [21]. Furthermore, the lack of defined, highly reproducible, and ethically sourced biological scaffolds remains a bottleneck for large-scale industrial applications.

Looking toward the future, the integration of an active, functional immune system into three-dimensional models represents the most critical frontier in preclinical research. The explosive success of immune checkpoint inhibitors and adoptive cellular therapies necessitates the development of sophisticated platforms capable of modeling the complex interactions between tumor cells, immunosuppressive stroma, and infiltrating cytotoxic lymphocytes. Advanced microfluidic models are currently being engineered to simulate the intricate cascade of immune cell recruitment, rolling, adhesion, extravasation, and targeted tumor cell lysis. The continuous refinement of these immuno-competent, spatially complex models will undoubtedly revolutionize our understanding of tumor immunology and exponentially accelerate the discovery of next-generation immunotherapeutics.

## 5. Conclusion

The profound transition from conventional planar cell cultures to advanced three-dimensional modeling techniques represents one of the most critical paradigm shifts in the history of biomedical research. The pervasive failure of oncological clinical trials is an unequivocal testament to the inadequacy of highly simplified in vitro systems that strip away the essential spatial, mechanical, and biochemical realities of human biology. By meticulously reconstructing the intricate architecture of the tumor microenvironment, including the extracellular matrix barriers, the profound metabolic and hypoxic gradients, and the dynamic interplay with surrounding stromal populations, three-dimensional models have fundamentally transformed our capacity to evaluate pharmacological efficacy. The ability of patient-derived organoids to faithfully preserve the unique genetic and phenotypic heterogeneity of primary human tumors has established a powerful new foundation for the practice of precision oncology. This methodology empowers clinicians to transition from a generalized, statistical approach to treatment toward highly personalized, empirically validated therapeutic regimens tailored to the specific functional vulnerabilities of an individual patient's disease.

While significant technical hurdles remain regarding assay standardization, throughput scalability, and the precise emulation of systemic immune responses, the rapid convergence of materials science, microfluidic engineering, and advanced computational imaging is consistently eroding these limitations. As these sophisticated spatial technologies continue to evolve, mature, and integrate into standard pharmaceutical development pipelines, they will undoubtedly play an indispensable role in reducing the immense attrition rates of novel therapeutics. Ultimately, the

comprehensive adoption of three-dimensional tumor models stands to drastically accelerate the translation of fundamental scientific discoveries into durable, life-saving clinical interventions.

**References**

[1] Li, Y., Yang, J., Yang, Z., Li, B., Han, L., He, H., ... & Tang, R. (2026, March). Make lvlms focus: Context-aware attention modulation for better multimodal in-context learning. In Proceedings of the AAAI Conference on Artificial Intelligence (Vol. 40, No. 8, pp. 6610-6618).

[2] Ren, Y., Wu, D., & Lopez–De Fede, A. (2022, June). Identification and Prediction of Low-Birthweight Baby Outcomes and Mom Risk Factors. In 2022 IEEE 10th International Conference on Healthcare Informatics (ICHI) (pp. 01-02). IEEE.

[3] Chu, Y. B., Li, J., Jia, P., Cui, J., Zhang, R., Kang, X., ... & Zhang, S. (2021). Irf1-and Egr1-activated transcription plays a key role in macrophage polarization: A multiomics sequencing study with partial validation. International Immunopharmacology, 99, 108072.

[4] Xie, C., Zhu, D., Wang, Z., Zhang, H., & Wei, Z. (2026). Explainable AI for Mental Health Detection from Social Media: A Comparative Study of Traditional Machine Learning and a Large Language Model. Available at SSRN 6429778.

[5] Lu, Y., Shi, T., Liu, W., Shang, D., Liu, X., Wang, Q., ... & Duan, X. (2025). Supramonomer-Based Glyco-Cationic Nanoparticles With GSH Depletion-Enhanced Drug/Gene Co-Delivery for Combination Therapy. Medicine Bulletin, 1(2), 171-181.

[6] Li, Y., Liao, X., Tang, S., Wang, Q., Lin, H., Yu, X., ... & Zhong, T. (2025). Potential Therapeutic Targets for Androgenetic Alopecia (AGA) in Obese Individuals as Revealed by a Gut Microbiome Analysis: A Mendelian Randomization Study. Nutrients, 17(11), 1892.

[7] Eraslan, G., Avsec, Ž., Gagneur, J., & Theis, F. J. (2019). Single-cell transcriptomics meets deep learning. Nature Methods, 16(11), 1083–1091.

[8] Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990). Basic local alignment search tool. Journal of Molecular Biology, 215(3), 403–410.

[9] Sun, L., Wang, Y., Zhao, L., Lu, L., Hou, F., Yin, C., ... & Fu, J. (2026). New Technologies Empower Hemophilic Arthropathy Treatment: Focusing on Regenerative Medicine, Molecular Targeting, and Gene Therapy. Medicine Bulletin.

[10] Cai, Lie, et al. "Deep learning model for breast shear wave elastography to improve breast cancer diagnosis (INSPiRED 006): An international, multicenter analysis." Journal of Clinical Oncology 43.32 (2025): 3482-3493.

[11] Ren, Y., Wu, D., Tong, Y., López-De Fede, A., & Gareau, S. (2023, November). Using machine learning methods to identify racial differences of low birthweight risks: Evidence from a state-level large-scale data in the us. In APHA 2023 Annual Meeting and Expo. APHA.

[12] Li, Y., Kang, Z., & Du, Y. (2026). Beyond PD-1/PD-L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy. Medicine Bulletin.

[13] Altschul, S. F., Madden, T. L., Schäffer, A. A., Zhang, J., Zhang, Z., Miller, W., & Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Research, 25(17), 3389–3402.

[14] Xie, C., Zhu, D., Wang, Z., Zhang, H., & Wei, Z. (2026). Compliance-Aware Discharge Agent for Auditable ICU Discharge Planning: A Pilot Feasibility Study Using Structured eICU Records. Available at SSRN 6429758.

[15] Yu, X., Zhang, Y., Yao, Y., Cho, W. C., & Shang, A. (2025). Biofilm-mediated immune dysregulation in chronic pulmonary diseases: mechanisms and clinical implications. Frontiers in Microbiology, 16, 1736384.

[16] Zou, F., Hao, H., Yang, M., Tan, C., Chen, L., Wu, J., & Wang, H. (2025). Enhancing cyclodextrin glycosyltransferase-mediated potato starch modification via plasma-activated water and twin-screw extrusion treatment. Food Chemistry, 491, 145247.

[17] Kwaan, M. R., Ren, Y., Wu, Y., & Xirasagar, S. (2021). Colonic stent use by indication and patient outcomes: a nationwide inpatient sample study. Journal of Surgical Research, 265, 168-179.

[18] Tao, X., Wu, X., Wu, H., Tu, L., Dong, M., Xiao, Y., ... & Zhong, T. (2026). A structural roadmap to gut health: A comprehensive review of edible insect chitin–protein complexes as alternative protein-derived, structure-specific prebiotics. International Journal of Biological Macromolecules, 151312.

[19] Zhao, H., Wang, Q., Zhan, G., Min, W., Zou, Y., & Cui, S. (2022). Need only one more point (NOOMP): Perspective adaptation crowd counting in complex scenes. IEEE Transactions on Multimedia, 25, 1414-1426.

[20] Estrada-Valbuena, J. J., Li, C., Parra-Giraldo, C. M., & Martínez-López, R. (2026). The Emerging Role of Microbial Extracellular Vesicles in Neuroinflammation and Neurodegeneration. Medicine Bulletin, 2(2), 231-238.

[21] Peng, Q., Planche, B., Gao, Z., Zheng, M., Choudhuri, A., Chen, T., ... & Wu, Z. (2024). 3d vision-language gaussian splatting. arXiv preprint arXiv:2410.07577.